Vifor Pharma Group Announces Successful Sale of OM Pharma
18.9.2020 08:00:00 EEST | Business Wire | Press release
Regulatory News:
Vifor Pharma has today announced the successful sale of 100% of the share capital of OM Pharma, a Vifor Pharma Group company to Optimus Holding Ltd. The terms of the deal include:
- A purchase consideration of MCHF 435 for 100% of the share capital
- An earn out related to potential future value gains on 20% of Optimus Holding Ltd. equity to be determined before the end of 2027 upon a trade sale, IPO or EBITDA multiple
This earn out together with the purchase consideration could result in a total transaction value exceeding MCHF 500. The deal is expected to close within 30 days.
OM Pharma is a Geneva-based company mainly active in the field of microbial derived immunotherapeutics and has developed strongly outside the core strategy of Vifor Pharma over the past few years.
Optimus Holding Ltd. is a Swiss Group, founded by Etienne Jornod together with long-standing Swiss entrepreneurs and Abdi Ibrahim (28.5%), a Turkey-based pharmaceutical company operating in 12 countries and exporting to 60 countries worldwide, as a strategic partner. Optimus Holding is fully committed to the sustainable growth of OM Pharma and to invest considerably in R&D to become a global biotechnology company focused on improving the lives of patients with respiratory and inflammatory diseases.
Stefan Schulze, CEO of Vifor Pharma Group comments, “I am very pleased to have successfully completed the competitive sale process of OM Pharma announced earlier this year that was overseen by Rothschild & Co. Optimus Holding Ltd. brings a wealth of expertise and OM Pharma will benefit from the knowledge, financial investment and operational synergies of the new owners. This sale strengthens our strategic focus and will enable the company to further invest into our exciting product pipeline, especially in our core therapeutic area of nephrology.”
Vifor Pharma Group is a global pharmaceuticals company. It aims to become the global leader in iron deficiency, nephrology and cardio-renal therapies. The company is the partner of choice for pharmaceuticals and innovative patient-focused solutions. Vifor Pharma Group strives to help patients around the world with severe and chronic diseases lead better, healthier lives. The company develops, manufactures and markets pharmaceutical products for precision patient care. Vifor Pharma Group holds a leading position in all its core business activities and consists of the following companies: Vifor Pharma; Vifor Fresenius Medical Care Renal Pharma (a joint company with Fresenius Medical Care); and OM Pharma. Vifor Pharma Group is headquartered in Switzerland, and listed on the Swiss Stock Exchange (SIX Swiss Exchange, VIFN, ISIN: CH0364749348). For more information, please visit viforpharma.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200917005959/en/
Contact information
Vifor Pharma Group:
Media Relations
Nathalie Ponnier
Global Head of Corporate Communications
+41 79 957 96 73
media@viforpharma.com
Investor Relations
Julien Vignot
Head of Investor Relations
+41 58 851 66 90
investors@viforpharma.com
Optimus Holding Ltd.:
Beatrix Benz
+41 79 256 77 73
beatrix.benz@benz-advisory.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ExaGrid Wins 4 Industry Awards at the Storage Awards25.6.2026 15:00:00 EEST | Press release
ExaGrid®, the world’s largest independent backup storage vendor providing Tiered Backup Storage with the most Comprehensive Security and AI-Powered Retention Time-Lock for Ransomware Recovery, today announced that the company was honored with four industry awards during the 23rd annual Storage Awards ceremony, “The Storries,” held in London on June 18, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260625584191/en/ The ExaGrid team headed to the stage four times throughout the Storage Awards ceremony in London to accept awards for ExaGrid Tiered Backup Storage. Photo courtesy of Storage Awards. ExaGrid was named Data Protection Company of the Year, Immutable Storage Company of the Year, Storage Company of the Year, andjointly received the Storage Solution of the Year - Corporate award with key channel partner Convergent Technology. ExaGrid continues to gain recognition for its Tiered Backup Storage, winning 11 industry
2026 Esri User Conference to Focus on Creating a More Intelligent World with GIS25.6.2026 15:00:00 EEST | Press release
Esri, the global leader in geographic information system (GIS) technology, today announced speakers and the conference theme for the 2026 Esri User Conference. The conference will be held from July 13 to 17 at the San Diego Convention Center in San Diego, California. This year's theme of "GIS—Creating a more intelligent world" will emphasize how GIS turns the science of "where" into shared understanding and coordinated action—at the scale of communities, enterprises, and the planet. Kristine Tompkins, president and cofounder of Tompkins Conservation, will join Esri president Jack Dangermond as a keynote speaker for this year's Plenary Session. Tompkins is the former CEO of Patagonia and has worked to create parklands, conserve marine spaces, and promote biodiversity over the past three decades. Tompkins and Dangermond will also be joined by special guests from the City of Allentown (Pennsylvania), NextEra Energy, Rete Ferroviaria Italiana, National Weather Service, National Geographic
Copeland Releases FY2025 Global Impact Report Highlighting Energy Efficiency, Safety and Innovation Progress25.6.2026 15:00:00 EEST | Press release
Copeland, a global leader in compression technologies and controls solutions, has released its second annual Global Impact Report. The report highlights the company’s Fiscal Year 2025 (FY25) progress across environmental sustainability, workplace safety and community impact, guided by its Purpose, Performance and People pillars. Copeland has advanced its sustainability commitments through three strategic areas of focus: Performance-Driven Decarbonization: Copeland reduced Scope 1 and Scope 2 greenhouse gas emissions by 20% year-over-year, advancing toward its Science Based Targets initiative (SBTi)-validated goal of a 55% absolute reduction by FY33, using FY23 as a baseline.2 Renewable energy procurement and onsite solar generation accounted for 58% of total global electricity use. Aligned Innovation: Copeland dedicated more than 4% of annual revenue to engineering, research and new product development in FY25. The company also accelerated average product testing and engineering cycles
SUTEL Deploys Tecnotree Platform to Modernize Mobile Prepaid Registration and Strengthen Digital Security and Trust in Costa Rica25.6.2026 14:26:00 EEST | Press release
The Superintendence of Telecommunications (SUTEL) is advancing the modernization of Costa Rica’s Mobile Prepaid Registration System through the implementation of a new technological platform provided by Tecnotree designed to strengthen user identification processes, enhance regulatory compliance, and improve the overall customer experience. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260625307287/en/ This initiative is part of SUTEL’s ongoing efforts to promote digital transformation within the telecommunications sector while reinforcing security, transparency, and trust in digital communications across the country. The new Tecnotree platform incorporates advanced identity verification mechanisms, biometric authentication capabilities, and fraud prevention tools that will enable a more efficient and secure registration process for prepaid mobile subscribers. By improving the reliability of subscriber information, the solu
MRM Health Strengthens Board with Michel Detheux as Chairman and Hans-Jürgen Wörle as Independent Director as MH002 Advances Through Phase 2b25.6.2026 14:00:00 EEST | Press release
MRM Health, a clinical-stage biotech developing microbiome-based therapies for immune-mediated diseases, today announced the appointment of two experienced industry leaders to its Board of Directors as the Company enters a pivotal phase of growth. With its lead program, MH002, in Phase 2b clinical development, recent FDA Fast Track designation and a €55 million Series B financing, MRM Health is strengthening its Board to support the Company through its next clinical, strategic and financing milestones. Michel Detheux, PhD, has been appointed Chairman of the Board of Directors, taking over from Werner Cautreels. Prof. Dr. med. Hans-Jürgen Wörle joins the Board as an Independent Director. “MRM Health is entering a pivotal phase, with MH002 advancing into Phase 2b clinical development and significant momentum across the business. The appointments of Michel and Hans-Jürgen significantly strengthen our Board with proven leaders in drug development, regulatory strategy, capital markets, stra
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom